10X Genomics (TXG) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $7.65B
- As of Nov 13, 2026
- P/E
- -112.49x
- Trailing twelve months
- P/B
- 9.13x
- Latest reported equity
- P/S
- 12.36x
- Trailing twelve months
- ROE
- -8.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
- Market cap
- $7.65B
- As of Nov 13, 2026
- P/E
- -112.49x
- Trailing twelve months
- P/B
- 9.13x
- Latest reported equity
- P/S
- 12.36x
- Trailing twelve months
- ROE
- -8.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 13, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
-112.49x
Net loss — not comparable
P/B
9.13x
P/S
12.36x
Earnings and dividend metrics▾
Earnings
EPS
—
Earnings per share
BPS
—
Book value per share
ROE
-8.1%
Return on equity
- ROE — shareholder equity shrank by 8.1% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 1.3% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $149M+1.3%
$152M
Jul–Sep '24
$149M
Jul–Sep '25
$151M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 6, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 1.3% from the same quarter a year earlier.
- Operating income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Nov 6, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Saxonov SergeChief Executive Officer · Nov 10, 2026Open-market sale31,000 shares · $1.9MAvg. price $62.91,019,249 shares held after
- Saxonov SergeChief Executive Officer · Sep 22, 2026Open-market sale25,000 shares · $2.0MAvg. price $81.2225
Show 5 price lots
- 9,900 shares × $81.8254$810K
- 9,300 shares × $80.9033$752K
- 2,800 shares × $82.365$231K
- 2,000 shares × $79.6195$159K
- 1,000 shares × $78.2284$78K
- SULIMAN SHEHNAAZDirector · Sep 22, 2026Open-market sale5,723 shares · $465KAvg. price $81.1931
Show 5 price lots
- 2,270 shares × $81.6699$185K
- 1,325 shares × $80.8164$107K
- 1,222 shares × $82.2768$101K
- 614 shares × $79.5114$49K
- 292 shares × $78.1959$23K
- Taich AdamChief Financial Officer · Sep 9, 2026Open-market sale46,388 shares · $3.0MAvg. price $64.5743
Show 3 price lots
- 31,428 shares × $64.3097$2.0M
- 13,754 shares × $65.2574$898K
- 1,206 shares × $63.6774$77K
- STUELPNAGEL JOHN RDirector · Sep 3, 2026Open-market sale20,000 shares · $1.2MAvg. price $61.7536
Show 3 price lots
- 7,012 shares × $60.6579$425K
- 6,814 shares × $62.1082$423K
- 6,174 shares × $62.6066$387K
- Saxonov SergeChief Executive Officer · Sep 1, 2026Gift100 shares · $0Avg. price $01,075,249 shares held after
- Saxonov SergeChief Executive Officer · Aug 26, 2026Open-market sale10,486 shares · $668KAvg. price $63.6945
Show 3 price lots
- 6,494 shares × $63.9768$415K
- 3,500 shares × $63.0229$221K
- 492 shares × $64.7465$32K
- Saxonov SergeChief Executive Officer · Aug 24, 2026Open-market sale18,545 shares · $1.2MAvg. price $63.02371,085,835 shares held after
- Taich AdamChief Financial Officer · Aug 24, 2026Open-market sale17,166 shares · $1.1MAvg. price $63.023362,732 shares held after
- Hindson Benjamin J.See Remarks · Aug 24, 2026Open-market sale13,818 shares · $871KAvg. price $63.0236488,182 shares held after
- SULIMAN SHEHNAAZDirector · Aug 24, 2026Open-market sale2,207 shares · $140KAvg. price $63.6511
Show 2 price lots
- 1,646 shares × $63.9664$105K
- 561 shares × $62.7259$35K
- Saxonov SergeChief Executive Officer · Aug 20, 2026Gift4,000 shares · $0Avg. price $01,104,380 shares held after
- Teichmann Sarah A.Director · Aug 14, 2026Open-market sale2,273 shares · $130KAvg. price $57.1528,058 shares held after
- Teichmann Sarah A.Director · Aug 13, 2026Open-market sale5,278 shares · $302KAvg. price $57.2930,331 shares held after
- STUELPNAGEL JOHN RDirector · Aug 11, 2026Open-market sale20,000 shares · $1.2MAvg. price $57.7528
Show 2 price lots
- 17,000 shares × $57.5812$979K
- 3,000 shares × $58.725$176K
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
10X Genomics (TXG) stock information
NASDAQ
10X Genomics (TXG) is listed on NASDAQ. Its market capitalization is about $7.6B. On trailing-twelve-month earnings the P/E ratio is -112.49, and the P/B ratio is 9.13. Return on equity is -8.1%. These figures are computed in-house from official filings and are reference information only.
10X Genomics — frequently asked questions
- What is the P/E ratio of 10X Genomics (TXG)?
- On a trailing-twelve-month basis, TXG trades at a P/E ratio of -112.49. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of 10X Genomics?
- TXG has a market capitalization of about $7.6B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.